Lupin has launched generic cancer drug Dasatinib Tablets, in multiple strengths, in the U.S. The product, bioequivalent to Bristol-Myers Squibb Company’s Sprycel Tablets, was developed by Lupin in partnership with Pharmascience Inc. The launch follows U.S. Food and Drug Administration’s approval for its abbreviated new drug application (ANDA). Under the agreement, TB Alliance will continue to lead the development process, while Lupin will provide its expertise in global manufacturing, regulatory affairs and supply chain to ensure global access to Telacebec. “Telacebec represents the kind of scientific innovation that has the potential to transform treatment for diseases that have long been neglected,” said TB Alliance President and CEO Mel Spigelman said.

Source: The Hindu February 02, 2026 15:44 UTC